104 related articles for article (PubMed ID: 8898930)
21. Serum beta 2-microglobulin in the initial staging and subsequent monitoring of monoclonal plasma cell disorders.
Garewal H; Durie BG; Kyle RA; Finley P; Bower B; Serokman R
J Clin Oncol; 1984 Jan; 2(1):51-7. PubMed ID: 6366146
[TBL] [Abstract][Full Text] [Related]
22. Serial serum free light chain measurements do not detect changes in disease status earlier than electrophoretic M-spike measurements in patients with intact immunoglobulin myeloma.
Uljon SN; Richardson PG; Schur PH; Anderson KC; Tanasijevic MJ; Lindeman NI
Clin Chim Acta; 2011 Mar; 412(7-8):562-8. PubMed ID: 21144845
[TBL] [Abstract][Full Text] [Related]
23. Transplantation as salvage therapy for high-risk patients with myeloma in relapse.
Lee CK; Barlogie B; Zangari M; Fassas A; Anaissie E; Morris C; Van Rhee F; Cottler-Fox M; Thertulien R; Muwalla F; Mazher S; Badros A; Tricot G
Bone Marrow Transplant; 2002 Dec; 30(12):873-8. PubMed ID: 12476279
[TBL] [Abstract][Full Text] [Related]
24. IgD multiple myeloma: Clinical, biological features and prognostic value of the serum free light chain assay.
Djidjik R; Lounici Y; Chergeulaïne K; Berkouk Y; Mouhoub S; Chaib S; Belhani M; Ghaffor M
Pathol Biol (Paris); 2015 Sep; 63(4-5):210-4. PubMed ID: 26294067
[TBL] [Abstract][Full Text] [Related]
25. Prognostic impact of serial measurements of serum-free light chain assay throughout the course of newly diagnosed multiple myeloma treated with bortezomib-based regimens.
Tacchetti P; Cavo M; Rocchi S; Pezzi A; Pantani L; Brioli A; Testoni N; Terragna C; Zannetti BA; Mancuso K; Marzocchi G; Borsi E; Martello M; Rizzello I; Zamagni E
Leuk Lymphoma; 2016 Sep; 57(9):2058-64. PubMed ID: 26763357
[TBL] [Abstract][Full Text] [Related]
26. Prognostic Value of Serum Free Light Chains Measurements in Multiple Myeloma Patients.
García de Veas Silva JL; Bermudo Guitarte C; Menéndez Valladares P; Rojas Noboa JC; Kestler K; Duro Millán R
PLoS One; 2016; 11(11):e0166841. PubMed ID: 27893836
[TBL] [Abstract][Full Text] [Related]
27. Peripheral blood lymphocyte surface antigen expression and prognosis in myeloma: Australian Leukaemia Study Group Study.
Joshua D; Wolf M; Matthews J; Tan L; Sheridan W; Pilkington G; Page F
Leuk Lymphoma; 1994 Jul; 14(3-4):303-9. PubMed ID: 7950919
[TBL] [Abstract][Full Text] [Related]
28. Prognosis of asymptomatic multiple myeloma.
Alexanian R; Barlogie B; Dixon D
Arch Intern Med; 1988 Sep; 148(9):1963-5. PubMed ID: 2458080
[TBL] [Abstract][Full Text] [Related]
29. [Role of the assay of serum beta 2 microglobulin in the clinical evaluation of myeloma].
Bataille R; Grenier J
Presse Med; 1986 Oct; 15(34):1723-5. PubMed ID: 2947132
[TBL] [Abstract][Full Text] [Related]
30. Response level and survival after conventional chemotherapy for multiple myeloma: a Finnish Leukaemia Group study.
Oivanen TM; Kellokumpu-Lehtinen P; Koivisto AM; Koivunen E; Palva I
Eur J Haematol; 1999 Feb; 62(2):109-16. PubMed ID: 10052714
[TBL] [Abstract][Full Text] [Related]
31. Interferon-alpha 2b added to melphalan-prednisone for initial and maintenance therapy in multiple myeloma. A randomized, controlled trial. The Nordic Myeloma Study Group.
Ann Intern Med; 1996 Jan; 124(2):212-22. PubMed ID: 8533996
[TBL] [Abstract][Full Text] [Related]
32. Prognostic factors in multiple myeloma: parametric analysis in each abnormal protein type.
Oguma S; Takatsuki K; Uchino H
Gan; 1981 Jun; 72(3):354-62. PubMed ID: 7319195
[TBL] [Abstract][Full Text] [Related]
33. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
[TBL] [Abstract][Full Text] [Related]
34. Different patterns of relapse after autologous peripheral blood stem cell transplantation in multiple myeloma: clinical results of 280 cases from the Spanish Registry.
Alegre A; Granda A; Martínez-Chamorro C; Díaz-Mediavilla J; Martínez R; García-Laraña J; Lahuerta JJ; Sureda A; Bladé J; de la Rubia J; Fernández-Rañada JM; San Miguel J; ; ;
Haematologica; 2002 Jun; 87(6):609-14. PubMed ID: 12031917
[TBL] [Abstract][Full Text] [Related]
35. Long-term survival of a patient with multiple myeloma--a cure? A case report.
Dutcher JP; Wiernik PH
Cancer; 1984 May; 53(10):2069-72. PubMed ID: 6704893
[TBL] [Abstract][Full Text] [Related]
36. Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
Han LY; Karavasilis V; Hagen Tv; Nicum S; Thomas K; Harrison M; Papadopoulos P; Blake P; Barton DP; Gore M; Kaye SB
Eur J Cancer; 2010 May; 46(8):1359-64. PubMed ID: 20303743
[TBL] [Abstract][Full Text] [Related]
37. Therapy for multiple myeloma with alternating non-cross-resistant chemotherapy combinations: heterogeneity of tumor responsiveness.
Morstyn G; Schechter GP; Ihde DC; Carney DN; Eddy JL; Cohen MH; Minna JD; Bunn PA
Cancer Treat Rep; 1984 Dec; 68(12):1439-46. PubMed ID: 6391662
[TBL] [Abstract][Full Text] [Related]
38. [Results of treatment of patients with advanced multiple myeloma with the vincristine-adriamycin-dexamethasone protocol].
Marisavljević D; Bosković D; Radosević N; Elezović I; Tomin D; Gotić M; Antunović P
Srp Arh Celok Lek; 1996; 124(11-12):292-6. PubMed ID: 9132962
[TBL] [Abstract][Full Text] [Related]
39. Normalization of free light chain kappa/lambda ratio is a robust prognostic indicator of favorable outcome in patients with multiple myeloma.
Iwama K; Chihara D; Tsuda K; Ugai T; Sugihara H; Nishida Y; Yamakura M; Takeuchi M; Matsue K
Eur J Haematol; 2013 Feb; 90(2):134-41. PubMed ID: 23210517
[TBL] [Abstract][Full Text] [Related]
40. Smoldering multiple myeloma: natural history and recognition of an evolving type.
Rosiñol L; Bladé J; Esteve J; Aymerich M; Rozman M; Montoto S; Giné E; Nadal E; Filella X; Queralt R; Carrió A; Montserrat E
Br J Haematol; 2003 Nov; 123(4):631-6. PubMed ID: 14616966
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
